Lv4
570 积分 2021-01-04 加入
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
27天前
已完结
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
1个月前
已完结
Innovative strategies for T cell engagers for cancer immunotherapy
1个月前
已完结
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
1个月前
已完结
T cell engagers in autoimmune diseases
1个月前
已完结
The next generation of antibody–drug conjugates
1个月前
已完结
Re-evaluating antibody–drug conjugate linker stability: assessment, interpretation, and clinical translation
2个月前
已完结
Bioanalytical Assay Strategies for The Development of Antibody–Drug Conjugate Biotherapeutics
2个月前
已完结
Bioanalytical Assay Strategies for The Development of Antibody–Drug Conjugate Biotherapeutics
2个月前
已关闭
Re-evaluating antibody–drug conjugate linker stability: assessment, interpretation, and clinical translation
2个月前
已完结
皖公网安备34019202002308
